newsfilter
← Latest News
Business Wire·

Cybin Selects Anxiety Disorder Indications for Proprietary Psychedelic Molecule CYB004

Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) ("Cybin" or the "Company"), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has selected social anxiety disorder ("SAD") and generalized anxiety disorder ("GAD") as the